The earnings call reflects a positive outlook with strong R&D progress and a promising partnership with Merck, despite challenges posed by financial market uncertainties affecting deal execution.

Company Guidance -

Q2 2025

During the Evaxion First Quarter 2025 Conference Call, CEO Christian Kanstrup highlighted key metrics and developments. The company is on track to achieve significant milestones, including a potential $10 million option exercise with Merck in the latter half of the year. Their business development target remains to secure at least two new deals by year-end. R&D progress was notable, with EVX-01 showing promising data; 80% of its new antigens elicited an immune response. Financially, Evaxion strengthened its position, ending Q1 with $17.8 million in cash, up from $6 million at the end of 2024, and forecasts a $14 million operational cash burn for the year, extending its runway to mid-2026. The net loss for Q1 was $1.6 million, while equity improved to $10.3 million. The company remains focused on its multi-partner strategy and aims to maintain its momentum in the coming months.

Partnership with Merck on Track

The partnership with Merck is progressing towards a potential option exercise in the second half of the year, which could result in a $10 million milestone payment.

Strong R&D Progress

EVX-01 continues to yield positive data with 80% of new antigens eliciting an immune response. The first patient has been dosed in a one-year trial extension.

Improved Financial Position

Cash position improved to $17.8 million from $6 million, providing a runway until mid-2026, with operational cash burn estimated at $14 million for the year.

Active Scientific Engagement

Evaxion had a strong presence at several scientific conferences, crucial for engaging with potential partners and solidifying their multi-partner strategy.

Evaxion Biotech (EVAX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EVAX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.58 / -	-0.6	―	―	―
May 27, 2025	2025 (Q1)	- / -0.01	0.15	-106.67% (-0.16)	―
Apr 01, 2025	2024 (Q4)	-0.70 / -0.01	0.15	-106.67% (-0.16)	―
Oct 31, 2024	2024 (Q3)	-1.57 / -0.20	-10.5	98.10% (+10.30)	―
Aug 14, 2024	2024 (Q2)	-1.27 / -0.60	-10.5	94.29% (+9.90)	―
May 28, 2024	2024 (Q1)	-5.47 / 0.15	-12	101.25% (+12.15)	―	―
Mar 27, 2024	2023 (Q4)	-8.00 / -8.00	-14.5	44.83% (+6.50)	―	―
Dec 19, 2023	2023 (Q3)	-9.50 / -10.50	-12	12.50% (+1.50)	―	―
Aug 18, 2023	2023 (Q2)	-10.75 / -10.50	-10	-5.00% (-0.50)	―
May 31, 2023	2023 (Q1)	- / -	-2.5	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EVAX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 27, 2025	$1.88	$2.36	+25.53%
Apr 01, 2025	$1.85	$1.66	-10.27%
Oct 31, 2024	$13.80	$13.35	-3.26%
Aug 14, 2024	$13.52	$13.76	+1.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Evaxion Biotech (EVAX) report earnings?

Evaxion Biotech (EVAX) is schdueled to report earning on Aug 07, 2025, Before Open (Not Confirmed).

What is Evaxion Biotech (EVAX) earnings time?

Evaxion Biotech (EVAX) earnings time is at Aug 07, 2025, Before Open (Not Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EVAX EPS forecast?

EVAX EPS forecast for the fiscal quarter 2025 (Q2) is -0.58.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing